These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 15539465)

  • 61. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Consensus Guidelines on the Application of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: Recommendations of the Irish Network for Biomarkers in Neurodegeneration.
    Miller AM; Begley E; Coen R; Doyle M; Dunne J; Hutchinson S; Kennelly SP; Kenny RA; Killeen RP; Lynch A; O'Dwyer S; O'Neill C; O'Sullvan SS; Rowan MJ; Sheehy N; McGuigan C; Lawlor BA
    Ir Med J; 2016 Dec; 109(10):483. PubMed ID: 28644588
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
    Franz G; Beer R; Kampfl A; Engelhardt K; Schmutzhard E; Ulmer H; Deisenhammer F
    Neurology; 2003 May; 60(9):1457-61. PubMed ID: 12743231
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preanalytical factors affecting the stability of matrix metalloproteinase-2 concentrations in cerebrospinal fluid.
    Sulik A; Wojtkowska M; Oldak E
    Clin Chim Acta; 2008 Jun; 392(1-2):73-5. PubMed ID: 18373981
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.
    Wahlund LO; Blennow K
    Neurosci Lett; 2003 Mar; 339(2):99-102. PubMed ID: 12614904
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
    Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
    BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau.
    Li G; Xiong K; Korff A; Pan C; Quinn JF; Galasko DR; Liu C; Montine TJ; Peskind ER; Zhang J
    J Alzheimers Dis; 2015; 47(4):883-7. PubMed ID: 26401768
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
    Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS;
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology.
    Rembach A; Evered LA; Li QX; Nash T; Vidaurre L; Fowler CJ; Pertile KK; Rumble RL; Trounson BO; Maher S; Mooney F; Farrow M; Taddei K; Rainey-Smith S; Laws SM; Macaulay SL; Wilson W; Darby DG; Martins RN; Ames D; Collins S; Silbert B; Masters CL; Doecke JD;
    Alzheimers Res Ther; 2015 Nov; 7(1):71. PubMed ID: 26581886
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M; Andreasen N; Blennow K
    Clin Chim Acta; 2003 Jun; 332(1-2):1-10. PubMed ID: 12763273
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
    Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
    Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Strong impact on plasma protein profiles by precentrifugation delay but not by repeated freeze-thaw cycles, as analyzed using multiplex proximity extension assays.
    Shen Q; Björkesten J; Galli J; Ekman D; Broberg J; Nordberg N; Tillander A; Kamali-Moghaddam M; Tybring G; Landegren U
    Clin Chem Lab Med; 2018 Mar; 56(4):582-594. PubMed ID: 29040064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer's disease when using CSF biomarkers.
    Algeciras-Schimnich A; Bornhorst JA
    Alzheimers Dement; 2024 May; 20(5):3657-3658. PubMed ID: 38288880
    [No Abstract]   [Full Text] [Related]  

  • 79. Alzheimer's disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C.
    Konen FF; Maier HB; Neyazi A; Bleich S; Neumann K; Skripuletz T
    Neurol Res Pract; 2023 Jun; 5(1):30. PubMed ID: 37381021
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Stability of volatile organic compound metabolites in urine at various storage temperatures and freeze-thaw cycles for 8 months.
    Pal VK; Kannan K
    Environ Pollut; 2024 Mar; 345():123493. PubMed ID: 38316251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.